Start here if you're new
what it is
Quince is a biotech trying to load a steroid into a patient's own red blood cells for a rare childhood disease.
how it gets paid
Last year Quince Therapeutics made n/a in revenue. eDSP / A-T program was the main engine at $0M, or 100% of sales.
what just happened
Quince closed 2024 with -$0.91 EPS for the year.
At a glance
C+ balance sheet — struggling to keep the lights on
50/100 earnings predictability — expect surprises
-$0.91 fy2024 eps est
1.1 beta
~$6M market cap
xvary composite: 35/100 — weak
What they do
Quince is a biotech trying to load a steroid into a patient's own red blood cells for a rare childhood disease.
AIDE → autologous intracellular drug encapsulation → your own red blood cells carry the medicine. So what: the body becomes the delivery truck. Quince has 32 employees and one lead product, so the edge is the mechanism, not scale. If safety data or launch execution breaks, the moat goes with it.
How they make money
n/a
annual revenue
eDSP / A-T program
$0M
AIDE platform
$0M
Option Care launch support
$0M
Corporate and other
$0M
The products that matter
rare-disease drug candidate
eDSP (encapsulated D-amino acid substance P)
lead asset · post-Phase 3 failure
This is the remaining lead asset after the Phase 3 NEAT trial in Ataxia-Telangiectasia failed in January 2026. With $0 revenue and no approved product to lean on, the pipeline is both the only source of upside and the reason the stock broke.
binary asset
Key numbers
$0M
long-term debt
No long-term debt means lenders are not first in line. That matters when the stock is worth only $6M.
32
employees
Thirty-two employees is a shoestring launch team. You are buying focus, not size.
$6M
market cap
The whole company is worth about $6M. One filing can move the tape.
1
lead product
One lead program means the outcome is concentrated. Good or bad, it lands fast.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (6% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for QNCX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Quince closed 2024 with -$0.91 EPS for the year.
Quarterly EPS stayed negative across 2024, ending at -$0.28 in the fourth quarter. That keeps the story in burn mode, not profit mode.
$0M
revenue
-$0.91
eps
n/a
n/a
the number that mattered
The year ended at -$0.91 EPS. That is the part you care about because it shows the company is still spending faster than it earns.
source: quarterly EPS history, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the central risk is specific, not generic: QNCX has to convert a failed lead program and a public listing into a deal, financing, or other workable path before the runway projected into early 2026 runs out.
med
the strategic process produces no transaction
Quince hired LifeSci Capital because the original plan broke after the Phase 3 miss. If no buyer, partner, or merger candidate shows up, the market is left valuing a failed program, a listing, and a shrinking cash balance.
At roughly $6M with $0 revenue, there is very little operating floor under the equity if the process ends with no deal.
med
cash runs down before management finds an answer
Projected runway only into early 2026 means time is doing real damage now. Every quarter without progress makes financing harder because the company has fewer choices and counterparties know it.
If capital is not raised or assets are not monetized, dilution, distressed terms, or restructuring move from abstract risk to live outcome.
med
listing pressure returns
The stock already showed how fast it can break below $1 after bad news. Nasdaq compliance requires 10 consecutive closes above that level, which sounds procedural until you remember a company under pressure may need market access fast.
A renewed compliance issue would hurt liquidity, narrow the buyer base, and make any financing conversation more expensive.
med
the failed Phase 3 result damages the value of everything else
A late-stage miss rarely stays contained to one line item. It changes how investors and potential partners price the rest of the science, especially when the company has no approved product and no revenue to offset the doubt.
Any haircut to pipeline credibility flows almost directly into equity value because there is no commercial business doing the stabilizing.
With $0 revenue, a roughly $6M market cap, and runway only into early 2026, this equity is effectively one long negotiation over what still has value.
source: institutional data · regulatory filings · risk analysis
Pay attention to
strategic
any update on the LifeSci process
A partnership, asset sale, reverse merger, or full-company sale is the only catalyst that can reset the story quickly. Silence is not neutral here. Silence usually means the clock kept ticking.
cash
the next cash-balance disclosure
Runway only into early 2026 means the next cash number matters more than the next EPS print. You do not need elegant modeling here. You need the latest balance-sheet reality.
listing
Nasdaq bid-price stability
The stock already showed how quickly it can slip below $1 after bad news. If that risk returns, financing and liquidity both get harder at the same time.
calendar
the next corporate update
Earnings themselves are secondary because revenue is $0. What you want from the next update is one thing: a clearer funding path, a real transaction signal, or both.
Analyst rankings
earnings predictability
50 / 100
in human-speak, the reported numbers are weak anchors because the real thesis is binary and event-driven. The next transaction headline matters more than another quarter of losses.
beta
1.1
Beta measures how a stock has moved versus the market. In plain English: when the market moved 10%, QNCX historically moved about 11%. That sounds ordinary. The actual risk is not market correlation. It is clinical failure and financing pressure.
source: institutional data
Institutional activity
institutional ownership data for QNCX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive